Meier, C.
Freiburghaus, K.
Bovet, C.
Schniering, J.
Allanore, Y.
Distler, O.
Nakas, C.
Maurer, B.
Funding for this research was provided by:
Forschungskredit UZH Postdoc (FK-19-046 to JS)
Stiftung Professor Dr. Max Cloëtta (To BM)
Article History
Received: 21 February 2020
Accepted: 2 December 2020
First Online: 14 December 2020
Competing interests
: CM, KF, CB, JS, CN: none to declare. OD had speaker fees from Actelion, Bayer, Boehringer Ingelheim, Medscape, Novartis, Roche, Menarini, Mepha, MSD, iQone, Pfizer, consultancy fees from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Bayer, Baecon Discovery, Blade Therapeutics, Boehringer, CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, GSK, Glenmark Pharmaceuticals, Inventiva, Italfarmaco, iQvia, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Roche, Sanofi, UCB, Amgen, Lilly, Target BioScience, Pfizer, project scoring fees from Abbvie, interview fees from Catenion, travel support from Pfizer, research grants from Actelion, Bayer, Boehringer Ingelheim, Competitive Drug Development International Ltd, Mitsubishi Tanabe, patent issued: mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143). BM had grant/research support from AbbVie, Protagen, Novartis, and congress support from Pfizer, Roche, Actelion, and MSD, speakers honorary from Novartis. In addition, B. Maurer has a patent mir-29 for the treatment of systemic sclerosis registered (US8247389, EP2331143). The real or perceived potential conflicts listed above are accurately stated. YA had consultancy relationships and/or has received research funding from Actelion, Bayer, Boehringer Ingelheim, ChemomAb, Genentech/Roche, Inventiva, Pfizer, Sanofi, Servier, in the area of potential treatments of scleroderma and its complications. AH received consulting fees and/or research funding from Actelion, ARXX, Bayer, Boehringer Ingelheim, Medscape, MSD and Roche.